The dosage is increased after every 4 weeks to maintain a maximum dosage of 15 mg
No First-Pass Effect : Like injections, nasal delivery skips the livers first-pass metabolism
Los agonistas del receptor GLP-1 (pptido similar al glucagn tipo 1), como semaglutida (Ozempic, Wegovy) y tirzepatida (Mounjaro, Zepbound, un agonista dual GIP/GLP-1), han transformado el manejo de la diabetes tipo 2 y la obesidad
The team carefully monitors each patients progress and adjusts the treatment duration to ensure optimal results
10.1371/journal.pone.0123454 136 SucicM.LueticK.JandricI.DrmicD.SeverA
Singh added that results from the ongoing FOCUS studya long-term ophthalmic endpoint trial evaluating semaglutide versus placebo in patients with type 2 diabeteswill be critical in clarifying the long-term retinal safety profile of GLP-1 therapies